Combined Modality Treatment for Patients With Stage IV Melanoma

Inclusion Criteria:

* Stage M1a, M1b, M1c biopsy proven metastatic melanoma.
* Ages 21-75.
* Karnofsky performance status greater than/equal to 80%.
* Measurable metastatic lesions by physical exam or scans.
* Acceptable CBC and blood chemistry results.
* Adequate hepatic and renal function.
* No active CNS metastatic disease. If CNS history is present, lesions must have been resected by surgery and/or gamma knife irradiation at least 3 months prior to study entry. The total number of CNS lesions at diagnosis should not exceed 3.
* Written informed consent.

Exclusion Criteria:

* Patients that have received more than 8 cycles of chemotherapy for metastatic melanoma.
* Patients who have received chemotherapy less than 4 weeks before beginning the trial.
* Patients who have received IFN alpha-2b or GM-CSF less than 4 weeks before beginning the trial.
* Patients who have received high-dose IL-2 less than 4 weeks before beginning the trial.
* Patients diagnosed with more than 3 CNS metastatic melanoma lesions.
* More than 5 hepatic lesions or any hepatic lesion larger than 5 cm.
* Baseline serum LDH greater than 1.1 times the upper limit of normal.
* Patients who are HIV positive.
* Patients who are pregnant.
* Patients who have receive corticosteroids or other agents less than 4 weeks before beginning the trial.
* Patients with asthma, angina pectoris or congestive heart failure.
* Patients with autoimmune disease such as lupus erythematosus, rheumatoid arthritis or thyroiditis.
* Patients with active infections including viral hepatitis.
* Patients with a history of any other neoplastic disease less than 5 years ago (carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin, however, can be admitted to the study).